Syneos Health, Inc. (SYNH) Prices 7M Share Secondary Offering

Syneos Health, Inc. (NASDAQ: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization, today announced the pricing of the previously announced underwritten secondary offering by affiliates of Thomas H. Lee Partners, L.P. and Advent International Corporation (the “Selling Stockholders”) of an aggregate of 7,000,000 shares of the Company’s common stock (the “Offering”). The Selling Stockholders have also granted the underwriter a 30-day option to purchase up to 1,050,000 additional shares of common stock. Syneos Health is not selling any shares and will not receive any proceeds from the proposed sale of the shares by the Selling Stockholders in the Offering. The Offering is expected to close on May 6, 2021, subject to customary closing conditions.

In addition, Syneos Health entered into an agreement with the Selling Stockholders to repurchase an aggregate of 400,000 shares of common stock from such Selling Stockholders in a private transaction, concurrently with the closing of the Offering, at the price at which the shares of common stock are sold to the public in the Offering, less underwriting discounts and commissions. The closing of the share repurchase is contingent on, and expected to occur simultaneously with, the closing of the Offering, subject to the satisfaction of other customary conditions. The closing of the Offering is not contingent on the closing of the share repurchase.

BofA Securities is acting as the sole underwriter of the Offering.

You May Also Be Interested In

• Volato (SOAR) Announces Board Changes
• Lipocine (LPCN) Files $150M Mixed Shelf
• ESGL Holdings (ESGL) Filed for 10M Share Offering by Selling Stockholders